Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size was valued at USD XX million in 2022 and is expected to expand at a CAGR of XX% during the forecast period, reaching USD XX million by 2028.
CAR T-cell therapy is a cancer treatment that uses a patient’s own immune system cells, called T cells, after these cells have been modified to better recognize and kill the patient’s cancer. The T cells are engineered in the laboratory and then expanded to large numbers and infused back into the patient. This type of treatment transfers an immune system into the patient that is capable of immediately killing the cancer. CAR stands for chimeric antigen receptor, which represents the genetically engineered portion of the T cell. The CAR part of the T cell contains proteins that allow the T cells to recognize the specific cancer cells as well as become highly activated to kill the cancer cells.
This report elaborates on the market size, market characteristics, and market growth of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Chimeric Antigen Receptor (CAR) T-Cell Therapy. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Report Include:
Market Size Estimates: Chimeric Antigen Receptor (CAR) T-Cell Therapy market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Chimeric Antigen Receptor (CAR) T-Cell Therapy market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Chimeric Antigen Receptor (CAR) T-Cell Therapy market
Segment Market Analysis: Chimeric Antigen Receptor (CAR) T-Cell Therapy market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Chimeric Antigen Receptor (CAR) T-Cell Therapy market situations and prospects in major and top regions and countries
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Chain: Chimeric Antigen Receptor (CAR) T-Cell Therapy market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry News, Policies by regions
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Porters Five Forces Analysis
Key players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market are covered in Chapter 2:
Formula Pharmaceuticals Inc.
Amgen
Celgene Corp.
Cellectis
Medimmune Llc/Astrazeneca
Avacta Life Sciences Ltd.
Eureka Therapeutics Inc.
Celyad SA
Protheragen Inc.
iCell Gene Therapeutics
Editas Medicine Inc.
Takeda Pharmaceuticals
Juno Therapeutics Inc. (A Celgene Company)
Shire Pharmaceuticals Inc.
Transgene SA
F. Hoffman La Roche AG
Gilead Sciences
Puretech Health
Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)
Bellicum Phamaceuticals
Servier Laboratories
Bluebird Bio
Mustang Bio Inc.
Novartis AG
Noile-Immune Biotech
In Chapter 6 and Chapter 9, on the basis of types, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2018 to 2028 is primarily split into:
Acute Lymphoblastic Leukemia (ALL)
Advanced Lymphomas
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2018 to 2028 covers:
Children
Adult
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Chimeric Antigen Receptor (CAR) T-Cell Therapy market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Chimeric Antigen Receptor (CAR) T-Cell Therapy market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Chimeric Antigen Receptor (CAR) T-Cell Therapy market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Chimeric Antigen Receptor (CAR) T-Cell Therapy market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
CAR T-cell therapy is a cancer treatment that uses a patient’s own immune system cells, called T cells, after these cells have been modified to better recognize and kill the patient’s cancer. The T cells are engineered in the laboratory and then expanded to large numbers and infused back into the patient. This type of treatment transfers an immune system into the patient that is capable of immediately killing the cancer. CAR stands for chimeric antigen receptor, which represents the genetically engineered portion of the T cell. The CAR part of the T cell contains proteins that allow the T cells to recognize the specific cancer cells as well as become highly activated to kill the cancer cells.
This report elaborates on the market size, market characteristics, and market growth of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Chimeric Antigen Receptor (CAR) T-Cell Therapy. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Report Include:
Market Size Estimates: Chimeric Antigen Receptor (CAR) T-Cell Therapy market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Chimeric Antigen Receptor (CAR) T-Cell Therapy market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Chimeric Antigen Receptor (CAR) T-Cell Therapy market
Segment Market Analysis: Chimeric Antigen Receptor (CAR) T-Cell Therapy market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Chimeric Antigen Receptor (CAR) T-Cell Therapy market situations and prospects in major and top regions and countries
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Chain: Chimeric Antigen Receptor (CAR) T-Cell Therapy market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry News, Policies by regions
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Porters Five Forces Analysis
Key players in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market are covered in Chapter 2:
Formula Pharmaceuticals Inc.
Amgen
Celgene Corp.
Cellectis
Medimmune Llc/Astrazeneca
Avacta Life Sciences Ltd.
Eureka Therapeutics Inc.
Celyad SA
Protheragen Inc.
iCell Gene Therapeutics
Editas Medicine Inc.
Takeda Pharmaceuticals
Juno Therapeutics Inc. (A Celgene Company)
Shire Pharmaceuticals Inc.
Transgene SA
F. Hoffman La Roche AG
Gilead Sciences
Puretech Health
Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)
Bellicum Phamaceuticals
Servier Laboratories
Bluebird Bio
Mustang Bio Inc.
Novartis AG
Noile-Immune Biotech
In Chapter 6 and Chapter 9, on the basis of types, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2018 to 2028 is primarily split into:
Acute Lymphoblastic Leukemia (ALL)
Advanced Lymphomas
Others
In Chapter 7 and Chapter 10, on the basis of applications, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market from 2018 to 2028 covers:
Children
Adult
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Chimeric Antigen Receptor (CAR) T-Cell Therapy market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Chimeric Antigen Receptor (CAR) T-Cell Therapy market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Chimeric Antigen Receptor (CAR) T-Cell Therapy market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Chimeric Antigen Receptor (CAR) T-Cell Therapy market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
